Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Associations of Two Common Polymorphisms in MTHFR Gene with Blood Lipids and Therapeutic Efficacy of Simvastatin

Author(s): Shanqun Jiang*, Yu Liu, Cuiping Lu, Yajie Li and Scott A. Venners

Volume 28, Issue 26, 2022

Published on: 04 August, 2022

Page: [2167 - 2176] Pages: 10

DOI: 10.2174/1381612828666220623102537

Price: $65

Abstract

Background: Cardio-cerebrovascular disease is an important public health challenge worldwide, and its complex etiology has not been elucidated fully. The study investigated the relationship between two common polymorphisms, C677T and A1298C in the methylenetetrahydrofolate reductase (MTHFR) gene, baseline lipids and the lipid-lowering efficacy of simvastatin in a Chinese hyperlipidemic population.

Methods: All participants were recruited from Anhui, China. By the extreme sampling method, we selected subjects with a low response (n=108) and high response (n=106) based on their adjusted lipid-lowering response to simvastatin administrated for 8 consecutive weeks. Both MTHFR C677T and A1298C loci were genotyped by the MALDI-TOF MS platform. Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were measured at baseline and after 8 weeks of oral 20 mg/d tablets of simvastatin.

Results: Patients with the 677TT genotype had significantly higher baseline TC, HDL-C, and change in HDL-C (ΔHDL-C) levels after treatment than those with 677CC+CT genotypes (β = 0.207, P = 0.045; β = 0.182, P = 0.026; and β = 0.16, P = 0.002, respectively). Patients with 1298AC+CC genotypes had significantly higher baseline LDL-C and change in LDL-C (ΔLDL-C) levels (β = 0.276, P =0.043; β = 0.359, P = 0.025, respectively) than those with 1298AA genotype. We found statistical interactions between the two SNPs in association with baseline HDL-C (P for interaction = 0.034), TC (P for interaction = 0.069), and TG (P for interaction = 0.034). Baseline TC (P = 0.027) and HDL-C (P = 0.046) and change in HDL-C (P = 0.019) were different among those with the MTHFR A-T haplotype compared with A-C.

Conclusion: Our major findings suggest that both MTHFR C677T and A1298C polymorphisms could be important genetic determinants of lipid traits and drug efficacy of simvastatin. This will contribute to a better understanding of strategies for personalized medication in Chinese patients with dyslipidemia.

Keywords: MTHFR, polymorphism, haplotype, dyslipidemia, efficacy, simvastatin.

« Previous Next »
[1]
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: A report from the American Heart Association. Circulation 2015; 131(4): e29-e322.
[http://dx.doi.org/10.1161/CIR.0000000000000152] [PMID: 25520374]
[2]
Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res 2017; 120(3): 472-95.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.308398] [PMID: 28154098]
[3]
Rendeli C, Ausili E, Castorina M, Antuzzi D, Tabacco F, Caldarelli M. Homocysteine, folate, lipid profile and MTHFR genotype and disability in children with myelomeningocele. Childs Nerv Syst 2006; 22(10): 1316-21.
[http://dx.doi.org/10.1007/s00381-006-0056-0] [PMID: 16602021]
[4]
Gryn SE, Hegele RA. Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother 2015; 16(8): 1255-62.
[http://dx.doi.org/10.1517/14656566.2015.1041504] [PMID: 25920750]
[5]
Wan L, Li Y, Zhang Z, Sun Z, He Y, Li R. Methylenetetrahydrofolate reductase and psychiatric diseases. Transl Psychiatry 2018; 8(1): 242.
[http://dx.doi.org/10.1038/s41398-018-0276-6] [PMID: 30397195]
[6]
Moll S, Varga EA. Homocysteine and MTHFR Mutations. Circulation 2015; 132(1): e6-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013311] [PMID: 26149435]
[7]
Luo Z, Lu Z, Muhammad I, et al. Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: A systematic review and updated meta-analysis. Lipids Health Dis 2018; 17(1): 191.
[http://dx.doi.org/10.1186/s12944-018-0837-y] [PMID: 30115070]
[8]
Lv QQ, Lu J, Sun H, Zhang JS. Association of methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with ischemic stroke in the Eastern Chinese Han population. Genet Mol Res 2015; 14(2): 4161-8.
[http://dx.doi.org/10.4238/2015.April.27.31] [PMID: 25966188]
[9]
Levin BL, Varga E. MTHFR: Addressing genetic counseling dilemmas using evidence-based literature. J Genet Couns 2016; 25(5): 901-11.
[http://dx.doi.org/10.1007/s10897-016-9956-7] [PMID: 27130656]
[10]
Jiang S, Zhao R, Pan M, Venners SA, Zhong G, Hsu YH. Associations of MTHFR and MTRR polymorphisms with serum lipid levels in Chinese hypertensive patients. Clin Appl Thromb Hemost 2014; 20(4): 400-10.
[http://dx.doi.org/10.1177/1076029612467226] [PMID: 23188888]
[11]
Li WX, Lv WW, Dai SX, Pan ML, Huang JF. Joint associations of folate, homocysteine and MTHFR, MTR and MTRR gene polymorphisms with dyslipidemia in a Chinese hypertensive population: A cross-sectional study. Lipids Health Dis 2015; 14(1): 101.
[http://dx.doi.org/10.1186/s12944-015-0099-x] [PMID: 26337056]
[12]
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21(2): 263-5.
[http://dx.doi.org/10.1093/bioinformatics/bth457] [PMID: 15297300]
[13]
Haplo Stats User Manual.. Available from: http://faculty.washington.edu/kenrice/sisg/haplo.stat.pdf
[14]
Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55(1): 56-65.
[http://dx.doi.org/10.1159/000071811] [PMID: 12890927]
[15]
Li YY. Methylenetetrahydrofolate reductase C677T gene polymorphism and coronary artery disease in a Chinese Han population: A meta-analysis. Metabolism 2012; 61(6): 846-52.
[http://dx.doi.org/10.1016/j.metabol.2011.10.013] [PMID: 22146089]
[16]
Wen C, Lv JF, Wang L, Zhu WF, Wan FS, Wang XZ. Association of a methylene tetrahydrofolate reductase C677T polymorphism with several blood chemical levels in a Chinese population. Genet Test Mol Biomarkers 2015; 19(1): 24-9.
[http://dx.doi.org/10.1089/gtmb.2014.0213] [PMID: 25489783]
[17]
Chmurzynska A, Malinowska AM, Twardowska-Rajewska J, Gawecki J. Elderly women: Homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism). Nutrition 2013; 29(6): 841-4.
[http://dx.doi.org/10.1016/j.nut.2012.09.015] [PMID: 23298970]
[18]
Mahesh M, Cheng G, Khalighi K. Association of Methylenetetrahydrofolate Reductase (MTHFR) A1298C polymorphism with lower high-density lipoprotein cholesterol level. Ann Clin Lab Sci 2019; 49(2): 232-6.
[PMID: 31028069]
[19]
Liu Y, Li K, Venners SA, et al. Individual and joint associations of methylenetetrahydrofolate reductase c677t genotype and plasma homocysteine with dyslipidemia in a chinese population with hypertension. Clin Appl Thromb Hemost 2017; 23(3): 287-93.
[http://dx.doi.org/10.1177/1076029615609686] [PMID: 26442927]
[20]
Wei LK, Au A, Menon S, et al. Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and ischemic stroke: Meta-Analysis. J Stroke Cerebrovasc Dis 2017; 26(11): 2482-93.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.05.048] [PMID: 28760411]
[21]
Lin Z, Li Q, Sun Y, et al. Interactions between genetic variants involved in the folate metabolic pathway and serum lipid, homocysteine levels on the risk of recurrent spontaneous abortion. Lipids Health Dis 2019; 18(1): 143.
[http://dx.doi.org/10.1186/s12944-019-1083-7] [PMID: 31200713]
[22]
El Hajj Chehadeh SW, Jelinek HF, Al Mahmeed WA, et al. Relationship between MTHFR C677T and A1298C gene polymorphisms and complications of type 2 diabetes mellitus in an Emirati population. Meta Gene 2016; 9: 70-5.
[http://dx.doi.org/10.1016/j.mgene.2016.04.002] [PMID: 27222819]
[23]
Santana Bezerra H, Severo de Assis C, Dos Santos Nunes MK, et al. The MTHFR promoter hypermethylation pattern associated with the A1298C polymorphism influences lipid parameters and glycemic control in diabetic patients. Diabetol Metab Syndr 2019; 11(1): 4.
[http://dx.doi.org/10.1186/s13098-019-0399-9] [PMID: 30675189]
[24]
Conkbayir C, Fahrioglu Yamaci R, Gencer P, et al. Impact of genetic defects on coronary atherosclerosis among Turkish cypriots. Heart Surg Forum 2017; 20(5): E223-9.
[http://dx.doi.org/10.1532/hsf.1587] [PMID: 29087287]
[25]
Liao D, Yang X, Wang H. Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease. Clin Chem Lab Med 2007; 45(12): 1652-9.
[http://dx.doi.org/10.1515/CCLM.2007.358] [PMID: 18020970]
[26]
Fernández-Sanlés A, Sayols-Baixeras S, Subirana I, Degano IR, Elosua R. Association between DNA methylation and coronary heart disease or other atherosclerotic events: A systematic review. Atherosclerosis 2017; 263: 325-33.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.05.022] [PMID: 28577936]
[27]
Zidan HE, Rezk NA, Mohammed D. MTHFR C677T and A1298C gene polymorphisms and their relation to homocysteine level in Egyptian children with congenital heart diseases. Gene 2013; 529(1): 119-24.
[http://dx.doi.org/10.1016/j.gene.2013.07.053] [PMID: 23933414]
[28]
Woo CW, Siow YL, Pierce GN, et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. Am J Physiol Endocrinol Metab 2005; 288(5): E1002-10.
[http://dx.doi.org/10.1152/ajpendo.00518.2004] [PMID: 15644462]
[29]
Visram M, Radulovic M, Steiner S, et al. Homocysteine regulates fatty acid and lipid metabolism in yeast. J Biol Chem 2018; 293(15): 5544-55.
[http://dx.doi.org/10.1074/jbc.M117.809236] [PMID: 29414770]
[30]
Mikael LG, Rozen R. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Cardiovasc Res 2008; 80(1): 151-8.
[http://dx.doi.org/10.1093/cvr/cvn157] [PMID: 18540024]
[31]
Hu M, Tomlinson B. Lipid-lowing pharmacogenomics in Chinese patients. Expert Rev Cardiovasc Ther 2013; 11(8): 985-97.
[http://dx.doi.org/10.1586/14779072.2013.814839] [PMID: 23952137]
[32]
Jiang S, Chen Q, Venners SA, et al. Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia. Cardiovasc Ther 2013; 31(4): e27-33.
[http://dx.doi.org/10.1111/1755-5922.12002] [PMID: 23865383]
[33]
Maitland-van der Zee AH, Lynch A, Boerwinkle E, et al. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: The GenHAT study. Pharmacogenet Genomics 2008; 18(8): 651-6.
[http://dx.doi.org/10.1097/FPC.0b013e3282fe1759] [PMID: 18622257]
[34]
Cerda A, Hirata MH, Hirata RD. Molecular mechanisms underlying statin effects on genes involved in the reverse cholesterol transport. Drug Metabol Drug Interact 2012; 27(2): 101-11.
[http://dx.doi.org/10.1515/dmdi-2012-0007] [PMID: 22706233]
[35]
Genvigir FD, Rodrigues AC, Cerda A, Hirata MH, Curi R, Hirata RD. ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells. Drug Metabol Drug Interact 2011; 26(1): 33-6.
[http://dx.doi.org/10.1515/dmdi.2011.101] [PMID: 21417795]
[36]
Luo Q, Zeng J, Li W, et al. Interaction of MTHFR gene with smoking and alcohol use and haplotype combination susceptibility to psoriasis in Chinese population. Immunol Res 2018; 66(4): 543-7.
[http://dx.doi.org/10.1007/s12026-018-9017-4] [PMID: 30084051]
[37]
Ulvik A, Ueland PM, Fredriksen A, et al. Functional inference of the methylenetetrahydrofolate reductase 677C > T and 1298A > C polymorphisms from a large-scale epidemiological study. Hum Genet 2007; 121(1): 57-64.
[http://dx.doi.org/10.1007/s00439-006-0290-2] [PMID: 17115185]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2025 Bentham Science Publishers | Privacy Policy